Form 4: AbbVie Director Susan E. Quaggin Reports Acquisition of Stock Equivalent Units

Director Susan E. Quaggin reports acquisition of AbbVie stock equivalent units as part of director fees.

Summary

• Susan E. Quaggin, a director of AbbVie Inc., filed a Form 4 on October 1, 2024, reporting a transaction on September 30, 2024.
• The transaction involved the acquisition of 75 stock equivalent units at a price of $197.48.
• These units were credited to a stock equivalent unit account under a grantor trust established by the director as payment for director fees.
• The balance of stock equivalent units following the reported transaction is 314, which includes units acquired through a dividend reinvestment feature.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to director compensation, indicating a neutral to slightly positive sentiment as it aligns director interests with shareholder value.

Positives

• The acquisition of stock equivalent units aligns the director's interests with those of the shareholders.
• The dividend reinvestment feature further increases the director's stake in the company.

Industry Context

This filing is a routine disclosure related to director compensation and stock ownership, common in publicly traded companies.

Comparison to Industry Standards

• Director compensation packages often include stock or stock equivalent units to align director interests with shareholder value, similar to practices at companies like Pfizer (PFE) and Johnson & Johnson (JNJ).
• The use of grantor trusts for deferred compensation is a standard practice to provide tax benefits and long-term incentives, comparable to executive compensation plans at Merck (MRK) and Eli Lilly (LLY).

Stakeholder Impact

• The transaction has a minor positive impact on shareholders by aligning the director's interests with the company's long-term performance.

Key Dates